Catalyst Pharmaceuticals Statistics
Share Statistics
Catalyst Pharmaceuticals has 119.27M shares outstanding. The number of shares has increased by 11.36% in one year.
| Shares Outstanding | 119.27M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.49% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 105.85M |
| Failed to Deliver (FTD) Shares | 543 |
| FTD / Avg. Volume | 0.06% |
Short Selling Information
The latest short interest is 6.01M, so 5.04% of the outstanding shares have been sold short.
| Short Interest | 6.01M |
| Short % of Shares Out | 5.04% |
| Short % of Float | 5.68% |
| Short Ratio (days to cover) | 8.2 |
Valuation Ratios
The PE ratio is 25.02 and the forward PE ratio is 15.26. Catalyst Pharmaceuticals 's PEG ratio is 0.2.
| PE Ratio | 25.02 |
| Forward PE | 15.26 |
| PS Ratio | 4.49 |
| Forward PS | 4.6 |
| PB Ratio | 4.61 |
| P/FCF Ratio | -32.53 |
| PEG Ratio | 0.2 |
Enterprise Valuation
Catalyst Pharmaceuticals Inc. has an Enterprise Value (EV) of 1.65B.
| EV / Earnings | 23.14 |
| EV / Sales | 4.15 |
| EV / EBITDA | 13.81 |
| EV / EBIT | 19.04 |
| EV / FCF | -30.09 |
Financial Position
The company has a current ratio of 2.88, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.88 |
| Quick Ratio | 2.68 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.82 |
| Cash Flow / Debt | 45.04 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0.18% and return on capital (ROIC) is 16.76%.
| Return on Equity (ROE) | 0.18% |
| Return on Assets (ROA) | 0.15% |
| Return on Capital (ROIC) | 16.76% |
| Revenue Per Employee | 2.38M |
| Profits Per Employee | 427.60K |
| Employee Count | 167 |
| Asset Turnover | 0.85 |
| Inventory Turnover | 5.4 |
Taxes
| Income Tax | 23.10M |
| Effective Tax Rate | 0.24 |
Stock Price Statistics
The stock price has increased by 48.54% in the last 52 weeks. The beta is 0.76, so Catalyst Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.76 |
| 52-Week Price Change | 48.54% |
| 50-Day Moving Average | 21.54 |
| 200-Day Moving Average | 18.13 |
| Relative Strength Index (RSI) | 45.79 |
| Average Volume (20 Days) | 952.98K |
Income Statement
In the last 12 months, Catalyst Pharmaceuticals had revenue of $398.20M and earned $71.41M in profits. Earnings per share was $0.67.
| Revenue | 398.20M |
| Gross Profit | 313.67M |
| Operating Income | 86.81M |
| Net Income | 71.41M |
| EBITDA | 119.69M |
| EBIT | 86.81M |
| Earnings Per Share (EPS) | 0.67 |
Balance Sheet
The company has $137.64M in cash and $3.56M in debt, giving a net cash position of $134.08M.
| Cash & Cash Equivalents | 137.64M |
| Total Debt | 3.56M |
| Net Cash | 134.08M |
| Retained Earnings | 121.27M |
| Total Assets | 772.01M |
| Working Capital | 433.60M |
Cash Flow
In the last 12 months, operating cash flow was $143.60M and capital expenditures -$198.52M, giving a free cash flow of -$54.92M.
| Operating Cash Flow | 143.60M |
| Capital Expenditures | -198.52M |
| Free Cash Flow | -54.92M |
| FCF Per Share | -0.52 |
Margins
Gross margin is 78.77%, with operating and profit margins of 21.8% and 17.93%.
| Gross Margin | 78.77% |
| Operating Margin | 21.8% |
| Pretax Margin | 23.73% |
| Profit Margin | 17.93% |
| EBITDA Margin | 30.06% |
| EBIT Margin | 21.8% |
| FCF Margin | -13.79% |
Dividends & Yields
CPRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 3.14% |
| FCF Yield | -2.16% |
Analyst Forecast
The average price target for CPRX is $31, which is 45.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $31 |
| Price Target Difference | 45.1% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 16.14 |
| Piotroski F-Score | 6 |